Investigational drugs for endometriosis.
Endometriosis is an enigmatic disease found in as many as 30% of reproductive age women. The symptoms for women who suffer from this malady vary but may include subfertility or chronic pelvic pain. Because endometriosis lesions rely on estradiol for growth, most of the existing drug regimens work by creating hypoestrogenism. Unfortunately, this leads to untoward side effects and alterations in ovulation and, subsequently, fertility potential. Newer drugs are currently under investigation that either create hypoestrogenemia more efficaciously or do not alter ovulation but still affect the growth of endometriosis. They target some of the pathophysiological pathways that are only now being elucidated, and include gonadotropin-releasing hormone antagonists, aromatase inhibitors, selective progesterone receptor modulators, angiogenesis inhibitors, matrix metalloprotease inhibitors, estrogen receptor beta-agonists and immune modulators.
Chlouber
Richard O
RO
Department of Obstetrics and Gynecology, University of Wisconsin, Madison 53792, USA.
Olive
David L
DL
Pritts
Elizabeth A
EA
D047072:Aromatase Inhibitors / Q000627:therapeutic use; D015507:Drugs, Investigational / Q000627:therapeutic use*; D004715:Endometriosis / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006727:Hormone Antagonists / Q000627:therapeutic use; D006801:Humans
D047072:Aromatase Inhibitors; D015507:Drugs, Investigational; D006727:Hormone Antagonists